A Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Lance Leopold, MD
Ascenta Therapeutics
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
35 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Facility name not stated
Barnaul, Russia
- Facility name not stated
Engel's, Russia
- Facility name not stated
Kazan', Russia
- Facility name not stated
Kursk, Russia
- Facility name not stated
Kuzmolovsky, Russia
- Facility name not stated
Moscow, Russia
- Facility name not stated
Saint Petersburg, Russia
- Facility name not stated
Sochi, Russia
- Facility name not stated
Stavropol, Russia
- Facility name not stated
Voronezh, Russia
- Facility name not stated
Yekaterinburg, Russia
- Facility name not stated
Colorado Springs, Colorado, United States
- Facility name not stated
New Port Richey, Florida, United States
- Facility name not stated
Ocoee, Florida, United States
- Facility name not stated
Fishers, Indiana, United States
- Facility name not stated
Burnsville, Minnesota, United States
- Facility name not stated
Las Vegas, Nevada, United States
- Facility name not stated
Albuquerque, New Mexico, United States
- Facility name not stated
Las Cruces, New Mexico, United States
- Facility name not stated
Raleigh, North Carolina, United States
- Facility name not stated
Kettering, Ohio, United States
- Facility name not stated
Eugene, Oregon, United States
- Facility name not stated
Spartanburg, South Carolina, United States
- Facility name not stated
Amarillo, Texas, United States
- Facility name not stated
Arlington, Texas, United States
- Facility name not stated
Austin, Texas, United States
- Facility name not stated
Dallas, Texas, United States
- Facility name not stated
Denton, Texas, United States
- Facility name not stated
Midland, Texas, United States
- Facility name not stated
Paris, Texas, United States
- Facility name not stated
Webster, Texas, United States
- Facility name not stated
Fairfax, Virginia, United States
- Facility name not stated
Norfolk, Virginia, United States
- Facility name not stated
Kennewick, Washington, United States
- Facility name not stated
Vancouver, Washington, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Oct 2007
- Primary completion
- 30 Sept 2010
- Completion
- 30 Sept 2010
- Last update posted
- 9 Nov 2010
- Registered enrollment
- 220
- Registry id
- NCT00571675
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.